Key Words T cell-dendritic cell interaction, osteoimmunology, TNF/TNFR super family molecules, osteoclast s Abstract TNF and TNFR family proteins play important roles in the control of cell death, proliferation, autoimmunity, the function of immune cells, or the organogenesis of lymphoid organs. Recently, novel members of this large family have been identified that have critical functions in immunity and that couple lymphoid cells with other organ systems such as bone morphogenesis and mammary gland formation in pregnancy. The TNF-family molecule RANK-L (RANK-L, TRANCE, ODF) and its receptor RANK are key regulators of bone remodeling, and they are essential for the development and activation of osteoclasts. Intriguingly, RANK-L/RANK interactions also regulate T cell/dendritic cell communications, dendritic cell survival, and lymph node formation; T cell-derived RANK-L can mediate bone loss in arthritis and periodontal disease. Moreover, RANK-L and RANK are expressed in mammary gland epithelial cells, and they control the development of a lactating mammary gland during pregnancy and the propagation of mammalian species. Modulation of these systems provides us with a unique opportunity to design novel therapeutics to inhibit bone loss in arthritis, periodontal disease, and osteoporosis.
INTRODUCTION
More than three decades ago, lymphotoxin and tumor necrosis factor were identified as products of lymphocytes and macrophages that caused the lysis of certain types of cells, especially tumor cells (1) (2) (3) . Large-scale sequencing efforts allowed for the identification of many related proteins, collectively referred to as TNF-and TNFR-related superfamily proteins. The receptors and ligands in this superfamily have unique structural attributes that couple them directly to signaling pathways for cell proliferation, survival, and differentiation (4) .
Inhibition of RANK-L function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases and completely blocks crippling in a rat model of arthritis. Intriguingly, RANK-L and RANK play essential roles in the formation of a lactating mammary gland in pregnancy and lactating. Thus, this system provided an unexpected molecular paradigm that links bone morphogenesis, T cell activation, and the organization of lymphoid tissues, with mammary gland formation required for the survival of mammalian species.
Remodeling of Bone
Morphogenesis and remodeling of bone involve the synthesis of bone matrix by osteoblasts and the coordinate resorption of bone by osteoclasts (10) . In fact, it has been estimated that ∼10% of the total bone mass in humans is being remodeled per year. Osteoblasts and osteoclasts arise from distinct cell lineages and maturation processes, i.e., osteoclasts arise from mesenchymal stem cells, whereas osteoclasts differentiate from hematopoietic monocyte/macrophage precursors ( Figure 1 ) (11) . Imbalances between osteoclast and osteoblast activities can arise from a wide variety of hormonal changes or perturbations of inflammatory and growth factors, resulting in skeletal abnormalities characterized by decreased (osteoporosis) or increased (osteopetrosis) bone mass.
Increased osteoclast activity is seen in many osteopenic disorders, including postmenopausal osteoporosis, Paget's disease, lytic bone metastases or rheumatoid arthritis, leading to increased bone resorption and crippling bone damage (10) . Various factors have been described including CSF-1 (M-CSF), IL-1, TGF-β, TGF-α, TNFα, TNFβ, IL-6, vitamin 1,25-hihydroxyvitamin D3, IL-11, calcitonin, PGE2, or parathyroid hormone (PTH), all of which affect osteoclastogenesis at distinct stages of development (11) . However, genetic ablation experiments have shown that these factors are not essential for osteoclast development in vivo. Due to the enormous social and economic impacts of bone loss, the crippling effects to human health, as well as the search to increase the human life-span without the side-effects of old age, it was of paramount importance to identify essential factors involved in osteoclast development and bone remodeling. These factors are the TNF-TNFR superfamily proteins RANK-L and RANK. We first discuss the genetic and functional links between bone metabolism and the immune system that explain bone loss associated with multiple diseases. Inhibition of RANK-L function via its natural decoy receptor osteoprotegerin (OPG) or small molecules might be the future treatment of choice to abolish osteoporosis, tooth loss, or crippling in arthritis.
anchored molecule and can be subsequently released from the cell surface as soluble homotrimeric molecules following proteolytic cleavage by the metalloproteasedisintegrin TNFα convertase (TACE) (16) . It remains to be seen whether TACE is indeed the critical protease required for the release of RANK-L from the cell surface. Although slight functional differences may exist, in our hands both soluble and membrane-bound RANK-L can function as potent agonistic ligands for osteoclastogenesis in vitro (13, 16, 17) . However, other authors have suggested that membrane-bound RANK-L may work more efficiently than soluble RANK-L (18) .
RANK-L is extensively expressed in osteoblast/stromal cells, primitive mesenchymal cells surrounding the cartilaginous anlagen and hypertrophied-chondrocytes. RANK-L expression can be upregulated by bone resorbing factors such as glucocorticoids, vitamin D3, IL-1, IL-6, IL-11, IL-17, TNFα, PGE 2 , or PTH (Table 1) (13, 15) . Using in vitro culture systems, it has been shown that RANK-L can both activate mature osteoclasts and mediate osteoclastogenesis in the presence of CSF-1 (13, 15) . rankl −/− mice display severe osteopetrosis, stunted growth, and a defect in tooth eruption, and rankl −/− osteoblasts cannot support osteoclastogenesis. However, these mice contain hematopoietic precursors that can differentiate into phenotypically and functionally mature osteoclasts in vitro in the presence of recombinant RANK-L and CSF-1. Importantly, osteoblast cell lines derived from rankl −/− mice do not support osteoclast formation, indicating that the defect in osteoclastogenesis observed in rankl −/− mice is due to an intrinsic defect in osteoblastic stroma. Whereas csf-1 mutant op/op mice display a developmental arrest in both monocyte/macrophage and osteoclast lineages, rankl −/− mice display normal monocyte/macrophage differentiation and normal differentiation of dendritic cells (DCs). The osteoclast defect in csf-1 mutant op/op mice is not absolute and older op/op mice do have, albeit only few, osteoclasts. Moreover, the defect in op/op mice can be reversed by transgenic overexpression of Bcl-2 in the osteoclast/monocyte lineage indicating that-in contrast to RANK-L-CSF-1 expression is not essential for osteoclast development (19) . Thus, RANK-L is a specific and essential differentiation factor for osteoclast precursors and an activation factor for mature osteoclasts (Figure 2 ).
RANK
The receptor for RANK-L is RANK (receptor activator of NFκB ligand, also known as TRANCE-R, or TNFRSF11A), a member of TNF-R superfamily. RANK is expressed as a transmembrane heterotrimer on the surface of hematopoietic osteoclast progenitors, mature osteoclasts, chondrocytes, and mammary gland epithelial cells (12, 20) . In vitro ligation of RANK with RANK-L results in osteoclastogenesis from progenitor cells and the activation of mature osteoclasts (20) (21) (22) . Mice with a genetic mutation of RANK are exact phenocopies of rankl −/− mice and have a complete block in osteoclast development that can be restored by reintroduction of RANK into bone marrow progenitor cells (23, 24) . The osteopetrosis observed in these mice can be reversed by transplantation of bone marrow from rag1 −/− mice, indicating that rank −/− mice have an intrinsic defect in osteoclast function (24) . Thus, the interaction between RANK-L expressed by stromal cells/osteoblasts and its receptor RANK expressed on osteoclast precursors is essential for osteoclastogenesis ( Figure 2 ). In human familial expansile osteolysis, a rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling (25) , a heterozygous insertion mutation in exon 1 of RANK has been noted that appears to increase RANK-mediated NFκB activation and thus might be causal for the disease. These genetic results in humans and mutant mice established the absolute dependency of osteoclast differentiation and activation of mature osteoclasts on the expression of RANK-L and RANK.
When RANK on osteoclasts is activated, it sends signals into the cells through adapter proteins (Figure 3 ). RANK contains 383 amino acids in its intracellular domain (residues 234-616), which contains three putative binding domains (termed I, II, and III) for tumor necrosis factor receptor-associated factors (TRAFs) (26) . Indeed, RANK interacts with TRAFs 1, 2, 3, 5, and 6 both in vitro and in cells (27) . Mapping of the structural requirements for TRAF/RANK interaction revealed multiple TRAF binding sites clustered in two distinct domains in the RANK cytoplasmic tail. These TRAF binding domains were shown to be functionally important for the RANK-dependent induction of NF-κB and c-Jun NH2-terminal kinase (JNK) activities. In particular, TRAF6 interacts with membrane-proximal determinants distinct from those binding TRAFs 1, 2, 3, and 5. When this membrane-proximal TRAF6 interaction domain was deleted, RANKmediated NF-κB signaling was completely inhibited, whereas JNK activation was only partially inhibited (26) (27) (28) (29) , suggesting that interaction with TRAFs is necessary for NF-κB activation but not essential for activation of the JNK pathway. Indeed mice lacking TRAF6 have bone phenotypes similar to that of rankl −/− and rank −/− mice due to a partial block in osteoclastogenesis and defective activation of mature osteoclasts (30) (31) (32) . It should be noted that TRAF6 mutant mice still have TRAP + osteoclasts (31), whereas NF-κB1/NF-κB2 double mutant mice lack TRAP + osteoclasts (33, 34) . Thus, TRAF6 is a critical factor involved in the activation of mature osteoclasts, but other TRAF6s (and possibly other molecules) appear to be able to partially substitute for the loss of TRAF6 during osteoclast development. In line with these data, osteoclastogenesis can be initiated in rank −/− mice by transfer of mutant RANK that lacks the TRAF6 binding site (24, and unpublished) .
RANK-L also activates the anti-apoptotic serine/threonine kinase Akt/PKB through a signaling complex involving c-Src and TRAF6 (35) . c-Src and TRAF6 interact with each other and with RANK following receptor engagement, and a deficiency in c-Src or the addition of Src family kinase inhibitors blocks TRANCEmediated Akt/PKB activation in osteoclasts. TRAF6, in turn, enhances the kinase activity of c-Src leading to tyrosine phosphorylation of downstream signaling molecules such as c-Cbl (35) . Moreover, RANK can recruit TRAF6, Cbl family scaffolding proteins, and the phospholipid kinase PI3-K in a ligand-and Srcdependent manner. RANK-L mediated Akt/PKB activation is defective in cbl-b −/− dendritic cells (36) . These findings implicate Cbl family proteins not only as negative regulators of signaling, but also as positive modulators of TNFR superfamily signaling. Moreover, these data provided the first evidence of a cross-talk between TRAF proteins and Src family kinases. In addition, it should be noted that inhibition of p38 kinases using SB203580 and overexpression of dominant negative p38α or MKK6 inhibit RANK-L-induced differentiation of the osteoclast-like cell line RAW264 (37) .
Osteoprotegerin-Protector of the Bone
Osteoprotegerin (OPG, "protector of the bone"; also known as osteoclastogenesis inhibitory factor, OCIF) is a secreted protein with homology to members of the TNF receptor family (13, 15, 38, 39) . The opg gene encodes a 44-kDa protein that is posttranslationally modified to a 55-kDa molecule through N-linked glycosylation. Although OPG is a member of the TNFR-family, whose membrane normally assembles as molecular trimers, OPG is secreted as a 110-kDa homodimer. OPG functions as a soluble decoy receptor to RANK-L and competes with RANK for RANK-L binding. Consequently, OPG is an effective inhibitor of osteoclast maturation and activation in vitro (13, 38) . High systemic levels of osteoprotegerin (OPG) in OPG transgenic mice cause osteopetrosis with normal tooth eruption and bone elongation, and these levels also inhibit the development and activity of endosteal, but not periosteal, osteoclasts (38) . By contrast, OPG-deficient mice display severe osteoporosis associated with a high incidence of fractures (40, 41) , indicating that the level of bone mass correlates with the levels of OPG in mice.
Expression of OPG in ST2 stromal cell line and human bone marrow stromal cells is downregulated by bone-resorbing factors such as vitamin D3 [1,25(OH)2D3], prostaglandin E2 (PGE2), or glucocorticoids and is upregulated by Ca 2+ ions and TGFβ (42, 43, 39) . OPG is also expressed in follicular dendritic cells (identified as FDCR-1) and is upregulated following CD40 ligating (44) . In addition to osteoporosis, some but not all OPG mutant mice develop calcification of their large arteries (40) , and RANK-L and RANK transcripts are detected in the calcified arteries of OPG −/− mice (45) . Transgenic OPG delivered from midgestation through adulthood does prevent the formation of arterial calcification in opg −/− mice by blocking a process resembling osteoclastogenesis (45) . These data indicate that the OPG/RANK-L/RANK signaling pathway may play an important role in both pathological and physiological calcification processes. Such findings may also explain the observed high clinical incidence of vascular calcification in the osteoporotic patient population (46) . Since woman with osteoporosis have increased incidence of strokes (47, 48) , OPG, RANK-L, and RANK may play, similar to the CD40 and CD40L system (49), a role in the pathogenesis of atherosclerosis, strokes, or heart attacks via a yet unknown regulation of endothelial cells.
All genetic and functional experiments by many different groups indicate that the balance between RANK-L-RANK signaling and the levels of biologically active OPG regulate development and activation of osteoclasts and bone metabolism ( Figure 2) . Intriguingly, all factors that inhibit or enhance bone resorption via osteoclasts act via regulation of RANK-L-RANK and/or OPG. Thus, it appears that the complex system of osteoclast-regulated bone-remodeling is only controlled by these three molecule. However, although RANK-L is also expressed in many other tissues than the bone, osteoclast development is restricted to the bone microenvironment suggesting that another tissue-specific factor may exist that acts in concert with RANK-L/RANK. It has recently been shown in vitro that TNFα and IL-1 can apparently induce the development of TRAP + osteoclasts in the absence of RANK/RANK-L (50, 51). However, in our own genetic experiments using RANK-deficient osteoclast progenitors, TNFα as well as IL-1-dependent osteoclastogenesis are strictly dependent on RANK expression. Thus, whereas TNFα and IL-1 appear to potentiate the development of osteoclasts (52) , presumably via activation of common second messenger systems such as NFκB activation, both of these molecules rely on the expression of RANK-L/RANK. It should be also noted that mutations of TNFα, TNFR1, or TNFR2 do not cause any alterations in bone metabolisms or osteoclast development/activation in vivo.
In addition to the association between RANK-L and OPG, OPG can also bind to the TNF-family molecule TRAIL at low stoichiometry (∼10,000 times less binding to TRAIL than to RANK-L) (53) . OPG-Fc binds TRAIL with an affinity of 3.0 nM, which is slightly weaker than the interaction of TRID-Fc or DR5-Fc with TRAIL. Functionally, high doses of OPG inhibit TRAIL-induced apoptosis of Jurkat cells and TRAIL can block the anti-osteoclastogenic activity of OPG (53) . These data suggest potential cross-regulatory mechanisms by OPG and TRAIL. However, it is still not known whether OPG-TRAIL interactions have any functional relevance in vivo. Importantly, OPG expression is induced by estrogen in cell lines and in vivo (54, 55) , which might explain postmenopausal osteoporosis in women: That is, reduced ovarian function leads to reduced estrogen levels and hence reduced OPG levels, which release RANK-L from the inhibition by the decoy receptor. Injection of OPG into ovariectomized female rats blocks bone loss and osteoporosis normally associated with the loss of ovarian function (38) . Thus, OPG and/or modulation of RANK-L-RANK function via small molecules are promising avenues to prevent postmenopausal osteoporosis. In essence, OPG appears to function in bone loss similar to insulin in diabetes: Injection of OPG prevents osteoclast activation and osteopenia in essentially every model system of osteoclast-mediated bone loss.
The Role of RANK-L and RANK in the Immune System
At around the same time we had the first evidence that RANK-L might play a role in osteoclast development, RANK-L (TRANCE) was independently cloned by two other groups as a molecule expressed on the surface of activated T cells (12, 14) . Both soluble and membrane-bound RANK-L is produced by activated CD4
+ and CD 8+ T cells (14, 17) . RANK-L is also expressed in lymph nodes, spleen, thymus and intestinal lymphoid patches (13) , and immature CD4 −
CD8
− thymocytes (12) . RANK-L expression in T cells is induced by antigen receptor engagement and is regulated by calcineurin, ERK1/ERK-2, and PKC-regulated signaling pathways (14, 17) . RANK is expressed on the surface of dendritic cells (DCs), mature T cells, and hematopoietic precursors; RANK-L-RANK interactions can induce cluster formation, Bcl-XL expression, survival, CD40 expression, and IL-12 production in DC ( Figure 4) (12, 14, 56) . In addition, OPG was found in a screen to identify novel genes expressed in follicular dendritic cells. OPG can be found on the cell surface of DCs probably by capturing of soluble OPG the cell membrane via binding of a hyalurinic acid binding region present in OPG (44) . Thus, like the interactions between CD40-L and CD40, or CD28 and CD80/CD86, the binding of RANK-L to RANK can regulate DC functions, T cell activation, and T cell-DC communication in vitro (12, 57) . Moreover, OPG may modulate this interaction.
Lymph Node Organogenesis
During the initial analyses of rankl −/− and later of rank mutant mice, a completely unexpected phenotype became evident: rankl −/− and rank −/− mice displayed complete absence of all lymph nodes (23, 24, 58) . Recent studies of mice deficient for lymphotoxin-α (LTα ) (59, 60) , LTβ (61, 62) , TNF-R1 (TNFRp55) (63) , LTβ receptor (LTβR) (64, 65) , or Id2 (66) have revealed important roles for each of these molecules in the development and organization of secondary lymphoid tissues. For example, TNFα activation of the TNF-R1 is required for the formation of splenic B lymphocyte follicles, follicular dendritic networks, and germinal center formation (63, 67) . Mice with disrupted LTα, LTβ, or LTβR genes lack lymph nodes, Peyer's patches, and follicular dendritic cells; such mice show altered splenic architecture (59, 61, 62, 65) . Thus, it was assumed that lymph node organogenesis and the development of Peyer's patches are always genetically linked. Surprisingly, rankl −/− and rank −/− mice lack all lymph nodes but display intact splenic architecture and develop Peyer's patches normally, suggesting that RANK-L and RANK have a specific and essential role in lymph node organogenesis. Importantly, RANK-L disruption provided the first evidence that development of lymph nodes and Peyer's patches can be genetically uncoupled.
The concerted activity of several cell lineages including fibroblasts, macrophages, reticular cells, and endothelial cells is required for the morphogenesis of primordial lymph nodes (8) . These primordial lymph nodes are subsequently seeded by T and B cells and CD4 + CD3 − LTβ + cells that differentiate into NK cells, antigen presenting cells, and follicular cells to form mature compact nodes (68) . In situ hybridization of normal lymph nodes has shown that RANK-Land RANK-expressing cells are present in lymph nodes, located mainly in the cortical areas adjacent to subcapsular sinuses (38) . The identity of these cells has yet to be determined. Since RANK and RANK-L are also expressed in the spleen and Peyer's patches, restricted RANK-L-RANK expression cannot account for the selective lack of lymph nodes. Moreover, because defective homing of rankl −/− lymphocytes was excluded as the cause of defective lymph node formation and normal bone marrow cells cannot rescue the lymph node defect in rankl −/− mice in chimeric transfer experiments, we speculated that RANK-L may act as a growth and/or survival factor on a lymph node organizing cell during embryonic development (58) . Recently it has been shown that the defective lymph node development in rankl −/− mice correlates with a significant reduction in lymphotoxin LTαβ + α4β7 + CD45 + CD4 + CD3 − cells and their failure to form clusters in rudimentary mesenteric (69) . Transgenic RANK-L-mediated restoration of lymph node development required LTαβ expression on CD45 + CD4 + CD3 − cells as lymph node formation could not be induced in LTα −/− mice. The authors proposed that both RANK-L and LTαβ regulate the colonization and cluster formation by CD45
− cells during lymph node organogenesis (69). Similar to rankl −/− and rank −/− mice, TNF-R1 −/− mice exhibit retained but small Peyer's patches (63, 67) , which suggests that both TNF-R1 and RANK-L may have a potential, albeit not essential, role in the formation of Peyer's patches. We have recently generated rankl-tnfr1 double knockout mice, and these mice completely lack Peyer's patches in the small intestine without further affecting the defects in splenic architecture observed in tnfr1 single mutant mice (Y. Kong and J. M. Penninger, unpublished). Thus, RANK-L is essential for lymph node formation and cooperates with the TNFR1 in the formation of Peyer's patches. The exact cellular and molecular mechanisms of RANK-L-RANK-regulated lymph node morphogenesis and the linkage between lymph node and Peyer's patch formation need to be tested.
RANK-L-RANK and Dendritic Cells-In Search of a Function?
Similar to the CD40L/CD40 system, interactions between RANK-L expressed on activated T cells and RANK expressed on dendritic cells can mediate DC survival via Bcl-XL induction and upregulation of the costimulatory molecule CD40 on DCs (Figure 4) (12, 56, 57) . Recently it has also been shown that RANK-L activates the anti-apoptotic serine/threonine kinase Akt/PKB through a signaling complex involving TRAF6 and c-Src on mature DCs and osteoclasts (35) . In addition to Akt/PKB activation, NF-κB and ERK are activated by RANK-L. Because NK-κB, ERK, and Akt/PKB promote cell survival by inhibiting apoptosis-inducing pathways, activation of these anti-apoptotic molecules seems to be at least partially responsible for the RANK-L-mediated DC survival. In addition to these in vitro studies, it has been shown that treatment of antigen-pulsed mature DCs with soluble RANK-L in vitro enhances the number and persistence of antigenpresenting DCs in the draining lymph nodes in vivo (56) . Furthermore, RANK-L treatment increased antigen-specific primary T cell responses. Interestingly, significant memory responses were observed only in mice injected with RANK-Ltreated DCs (56) . The increase in primary and memory T cell responses following vaccination with RANK-L-treated DCs could be due to enhanced/altered cytokine production such as expression of IL-12 and/or an increased number of antigenpulsed DCs.
Both CD40L and RANK-L have functional similarity, are expressed on activated T cells, and enhance the activation and survival of DCs (12, 57) . However, in contrast to CD40L/CD40, RANK-L/RANK signaling does not alter the expression of cell surface molecules such as MHC class II, CD80, CD86, and CD54. Whereas CD40L is primarily expressed on activated CD4
+ T cells, RANK-L is expressed on activated CD4
+ and CD8 + T cells (70, 17) . Moreover, the maximal level of RANK-L following the intial T cell activation event occurs at 48 h, and high levels of RANK-L expression are sustained until 96 h, while CD40L is rapidly expressed and downregulated (71) . Thus, CD40L-CD40 interactions may primarily control the initial priming stage, whereas RANK-L-RANK may act at later times than does CD40L during the immune response. For example, CD40L is essential for the T cell-dependent B cell responses such as germinal center formation, affinity maturation, and class switching (72, 73) . By contrast, in rankl −/− mice, germinal center formation, Ig class-switching, and the production of neutralizing antiviral Abs are not overtly affected, and all the B cell defects could be explained by the absence of lymph nodes (Y.-Y. Kong and J. M. Penninger, unpublished).
Inhibition of RANK-L in vivo using a soluble RANK-Fc molecule does not block the priming of LCMV-specific T cells, but it does impair proliferation of CD4 + T cells to the viral antigen at later time points after infection (74) . This impaired CD4
+ T cell response in RANK-Fc treated mice was especially apparent in the absence of CD40-expression. Thus, at later stages of the immune response, RANK-L can regulate CD40L-independent activation of CD4 + T helper cells (74) . These observations suggest that although CD40L and RANK-L have functional similarity and may cooperate, RANK-L and CD40-L may also have fundamentally different functions in the control of immune responses: CD40L regulates T/B responses, and RANK-L appears to have a role in memory T cell responses. However, in our laboratory using OPG transgenic mice and bone marrow chimeric mice that have normal lymph nodes but lack RANK-L expression on lymphocytes, we noted modulation of RANK-L does not impair the generation of cytototoxic T cells (P. Ohashi, J. N. Penninger, unpublished).
Only activated T cells, but not resting T cells, express RANK-L, which promotes dendritic cell survival (57) . DCs reside in tissues as immature cells and are specialized to capture and process antigens that lead to maturation of DCs in response to inflammatory stimuli. Mature DCs that have captured antigens migrate to T cell zones of secondary lymphoid organs by afferent lymphatics in order to present antigen to antigen-specific T cells. The T cell areas of secondary lymphoid organs represent the microenvironment that allows interactions between DCs, T cells, and B cells to initiate adaptive immune responses (reviewed in 75). Antigenbearing DCs are in direct contact with naïve antigen-specific T cells within the T cell areas of lymph nodes, and after interaction with T cells these DCs are eliminated rapidly (76) . Activated T cells induce apoptosis of DCs by producing the TNF-family molecules TRAIL, FasL, and TNFα. Accumulation and prolonged survival of DCs were reported in patients with human autoimmune lymphoproliferative syndrome type II. These patients had a caspase-10 mutation that rendered DCs resistant to TRAIL-induced cell death (77) . Thus, it appears that mature DCs have short life-spans and that mature DCs presenting antigens to T cells must be effectively eliminated to avoid excessive immune responses. The life span of DCs may be an important checkpoint to control for the induction of tolerance, priming, and chronic inflammation (78) .
Since both TRAIL and RANK-L are produced by activated T cells, the balance between RANK-L and TRAIL may influence DC survival (79) (80) (81) . Both RANK-L and TRAIL can bind to OPG (53) and OPG is made by DCs (44), which suggests that these factors control the fate of DCs. Based on these studies, various groups are currently trying to control the DC fate via RANK-L-RANK and OPG to modulate in vivo DC survival and to enhance the efficiency of DC-based vaccinations for anti-tumor therapy or the treatment of autoimmune diseases. In the final analyses of all the published genetic and functional studies on RANK-L, RANK, and OPG, it appears that although these molecules can influence some aspects of lymphocyte and DC functions, none of these molecules plays an essential function in T cells, B cells, or DCs that cannot be compensated for by other molecules such as CD40L/CD40. Thus, the essential and true function of RANKL/RANK in the immune system and communication between DCs and T cells need to be elucidated. For example, since expression of these molecules can be controlled by sex hormones (54, 82), we speculate that this system may control gender specific differences in immunity and could be involved in the higher incidence of autoimmune diseases like arthritis in women.
Lymphocyte Differentiation
Two principal genetic checkpoints regulate thymocyte differentiation. The first checkpoint, at the CD44 −
CD25
+ stage of development, depends on the expression of the pre-TCR on CD4 − CD8 − thymocyte precursors, which regulates expansion of these precursor cells. The second checkpoint regulates progression from CD4 +
CD8
+ immature to mature CD4 + or CD8 + thymocytes and correlates with positive thymocyte selection. Various mutations that arrest thymocyte development at the stage of pre-TCR expression have been reported (83) . All of these mutations either affect the pre-TCR complex directly or affect signaling molecules thought to be downstream of the pre-TCR. RANK-L expression has been detected on CD4
− CD8 − early thymocyte precursors (12) . RANK-L-deficient mice showed the block in the progression of CD4
− CD25 − thymocytes. This developmental defect does not reside in the thymic environment but is intrinsic to bone marrow-derived cells. These data suggested that the TNF-family cytokine RANK-L is important for the progression of CD25 +
CD44
− precursors to CD25 − CD44 − thymocytes at the stage of pre-TCR expression.
However, thymuses of newborn rankl −/− mice and differentiation of rankl −/− thymocytes in fetal thymic organ cultures appear normal, and the defects of thymocyte development in rankl −/− mice are only apparent at around 2 weeks of age, a phenotype reminiscent of thymic defects in mice lacking the pro-apoptotic bcl-2 family molecule bim (84) . Age-dependent interactions between RANK-Lexpressing thymocyte precursors and as-yet-unknown thymic stromal cells expressing RANK could contribute to early thymocyte development and thymocyte expansion, whereas later stages appear to be RANK-L independent. However, although RANK mRNA can be found in the thymus using in situ hybridization (58) , rank −/− mice do not display any obvious defects in thymocyte maturation (23, 24) . This difference in thymocyte differentiation is the only discernable distinction between rankl and rank mutant mice, and it suggests that RANK-L might act on another, yet unidentified, receptor during early thymocyte development. Additional work in the future should provide evidence of whether RANK-L and RANK indeed play a role in thymocyte development in a cell-autonomous fashion. For example, since RANK-L and OPG expression can be controlled by sex hormones, it would be interesting to test whether the thymocyte differentiation defects observed in rankl −/− , but not rank −/− mice, are dependent on sex hormone levels, a scenario that could explain age-related differences.
In addition to T cells, rankl and rank knockout mice have reduced numbers of mature B220
+ IgD + and B220 + IgM + B cells in the spleen and lymph nodes and slightly disorganized B cell areas in primary splenic follicles (20, 23, 58) . Since rankl and rank-null mice have no bone marrow cavities, the reduced cellularity of B cells could be due to an altered microenvironment or to changes in the composition of stromal cells outside the bone marrow cavity that affect B cell differentiation. For example, rankl −/− mice form an ectopically organized extramedullary hematopoietic tissue localized at the outer surfaces of vertebral bodies (58) . This tissue exhibits morphological and phenotypic features characteristic of hematopoiesis and proliferating precursor cells. Whether these hematopoietic islands in rankl −/− mice represent a defect in the homing of precursors during the switch from hepatic to bone marrow haematopoiesis, or an event secondary to osteopetrosis that interferes with the seeding of bone marrow cavities, remains to be determined.
In fetal liver cell chimeras, RANK-L regulates early B cell differentiation from the B220 +
CD43
+ CD25 − pro-B cell to the B220 + CD43 − CD25 + pre-B cell stage of development, which indicates that the TNF-family cytokine RANK-L is indeed a regulator of early B lymphocyte development (58) . Recent evidence in a new opg mutant mouse strain confirms the notion that the interplay of RANK-L-RANK and the molecular decoy receptor OPG may regulate the development and possibly the function of B lymphocytes (85) . Ex vivo, opg −/− pro-B cells have enhanced proliferation to IL-7, and type 1 transitional B cells accumulate in the spleens of opg −/− mice. Thus, loss of OPG may control B cell maturation. Moreover, it should be noted that OPG is a CD40-regulated gene in B cells and dendritic cells (85) and that prostaglandin E2 treatment can increase the amount of RANK-L messenger RNA in B220 + B cells in an estrogen-dependent manner (86) . Whether RANK-L acts as a survival factor required for early B and T cell development or whether RANK-L directly affects antigen receptor-driven lymphocyte maturation also remains to be seen.
T Cells and Bone-The Emergence of Osteoimmunology
Bone remodeling and bone loss are controlled by a balance between RANK-L/RANK and the RANK-L decoy receptor OPG. Since RANK-L is made by T cells following antigen-receptor stimulation, we asked the question whether T cell-derived RANK-L can indeed regulate the development and activation of osteoclasts, that is, whether activated T cells can modulate bone turnover via RANK-L. In an in vitro cell culture system, activated T cells can directly trigger osteoclastogenesis via RANK-L (17). Importantly, systemic activation of T cells in vivo leads to a RANK-L-dependent increase in osteoclastogenesis followed by bone loss. All in vitro and in vivo effects of T cells on osteoclasts could be blocked by the administration of the decoy receptor OPG (17) . Moreover, in a recent elegant study it has been shown that transgenic overexpression of RANK-L in T cells restores osteoclastogenesis in a rankl −/− background and partially restores normal bone marrow cavities (87) . These data showed that systemic activation of T cells leads to bone loss, indicating that, through their production of RANK-L, T cells are crucial mediators of bone loss in vivo. The results also provided a novel paradigm for T cells as regulators of bone physiology.
Because mutant mice that lack T cells still have normal bone cavities and tooth eruption, T cells are probably not required for normal bone homeostasis. However, chronic systemic T cell activation such as in autoimmune diseases, viral infections, or local inflammation within the bone due to metastasis, infections, and fractures, or joint inflammation in arthritis all probably attract T cells that then actively participate in bone remodeling via production of RANK-L. Moreover, glucocorticoids, which are used to treat autoimmune diseases and allergic disorders, strongly induce RANK-L expression and decrease OPG (15, 88) . Interestingly, our own unpublished results indicate that glucocorticoids and the TCR induce RANK-L expression in T cells. Thus, in certain diseases such as asthma, primary activation of T cells together with immunosuppressive treatment may in fact exacerbate osteopenia via synergistic activation of RANK-L expression on T cells. These findings provide a molecular explanation for bone loss associated with diseases having immune system involvement, such as adult and childhood leukemias, cancer metastasis, autoimmunity, and various viral infections. Inhibition of RANK-L function via OPG or a related molecule may therefore prevent bone destruction in multiple diseases.
RANK-L is a Critical Mediator of Crippling in Arthritis
One disease in which osteoclasts are a critical factor for disease progression is arthritis; bone loss results in life-long crippling. Arthritis in humans is characterized by synovial inflammation, erosion of bone and cartilage, severe joint pain and ultimately life-long crippling (89) . In Lewis rats, experimental induction of arthritis by subcutaneous injection of bacterial products in adjuvant leads to severe inflammation in the bone marrow and soft tissues surrounding joints, accompanied by extensive local bone and cartilage destruction, loss of bone mineral density, and crippling (90) . This condition in rats, called adjuvant-induced arthritis (AdA), mimics many of the clinical and pathological features of human RA. Lesions in rat AdA are dependent on T cell activation (91) , and T cells in the inflamed joints and draining lymph nodes of affected rats produce many pro-inflammatory cytokines (89) .
In this model system of severe arthritis that mimics many of the clinical and pathological features of human RA, RANK-L protein is expressed on the surface of synovial effector T cells isolated at the clinical onset of arthritis (17) . Inhibition of RANK-L via OPG had no effect on the severity of inflammation. However, OPG treatment completely abolished the loss of mineral bone density in the inflamed joints of these animals, in a dose-dependent manner. Histologically, OPG-treated arthritic rats exhibited minimal loss of cortical and trabecular bone, whereas untreated arthritic animals developed severe bone lesions characterized by partial to complete destruction of cortical and trabecular bone, and erosion of the articular cartilages. Bone destruction in untreated arthritic rats correlated with a dramatic increase in osteoclast numbers, whereas OPG treatment prevented the accumulation of osteoclasts (17) . These results showed that RANK-L is a key mediator of joint destruction and bone loss in adjuvant arthritis. Importantly, whereas untreated rats experienced severe crippling, rats treated with OPG at the onset of diseasesimilar to a patient consulting a doctor at the onset of joint swelling-did not show any signs of clinical crippling.
Alteration of cartilage structures leading to cartilage collapse constitutes a critical step in arthritic joint destruction. Controversy exists whether cartilage destruction occurs independently of bone loss, or whether damage to the subchondral bone indirectly causes cartilage deterioration (92) . In untreated arthritic rats, partial or complete erosion of the cartilage in both the central and peripheral regions of joint surfaces is observed. In striking contrast, the integrity of cartilage was preserved in OPG-treated arthritic rats. Neither cartilage erosion nor matrix degeneration in the centers of joint surfaces occurred in OPG-treated animals (17) . OPG could protect the cartilage by maintaining the underlying subchondral bone and insulating the overlying cartilage from the inflammatory cell infiltrates in the bone marrow. Since both RANK-L and RANK are expressed on chondrocytes (13, 20) , and rankl (58) as well as rank mutant mice (24) exhibit significant changes in the columnar alignment of chondrocytes at the growth plate, it is possible that RANK-L/RANK play a direct role in cartilage growth and cartilage homeostasis. These data provided the first evidence that inhibition of RANK-L activity by OPG can prevent cartilage destruction, a critical, irreversible step in the pathogenesis of arthritis.
It has become evident that the development of arthritis can occur in the absence of T cells (93) . Using in situ hybridization of inflamed rat joints and isolation of different cell populations from these joints, we could show that RANK-L is indeed expressed in lymphocytes, macrophages, and especially in synoviocytes (17) . In line with these findings, genetic ablation of RANK-L also does not prevent inflammation in an antibody-mediated model of arthritis using the K/BxN serum transfer model (94) . Multinucleated TRAP-positive osteoclast-like cells were abundant in resorption lacunae in areas of bone erosion in arthritic control mice, and they were completely absent in arthritic TRANCE/RANK-L knockout mice, demonstrating the absolute requirement for TRANCE/RANK-L in osteoclastogenesis in this serum transfer model of inflammatory arthritis (95) . Cartilage damage was still observed in both arthritic TRANCE/RANK-L knockout mice and arthritic control mice, but a trend toward milder cartilage damage in the TRANCE/RANK-L knockout mice was noted. Thus, TRANCE/RANK-L apparently is not required for cartilage destruction, but clearly plays an as-yet-unidentified modulatory role (95) . Moreover, inhibition of RANK-L via OPG prevents bone loss without affecting inflammation in a TNFα-induced arthritis model (96), indicating that TNFα triggered bone loss is critically dependent on RANK-L expression (S. Smolen, Vienna, personal communication). Whether OPG prevents bone in other animal models of arthritis needs to be tested.
To investigate whether RANK-L is implicated in human RA, we collected inflammatory cells from the synovial fluid of patients with adult or juvenile rheumatoid arthritis (RA) and patients with osteoarthritis, and we evaluated OPG and RANK-L expression. All RA and osteoarthritis patients ever tested (n > 40) exhibited RANK-L expression in inflammatory cells, whereas OPG expression was not detectable (17) . Thus, the correlation between RANK-L expression in inflamed joints and arthritis appears to be absolute. To distinguish which cells were producing RANK-L, inflammatory synovial fluids were separated into T and non-T cell populations. Consistent with our results in rats, both synovial T and non-T cell populations from RA patients expressed RANK-L, but not OPG. Fibroblasts isolated from the same adult RA joints failed to express RANK-L. These data confirm the findings in rodent adjuvant arthritis and suggest that RANK-L is the principal mediator of bone destruction in human arthritis.
A Molecular Scenario of T Cell-Regulated Bone Loss
In inflammatory or autoimmune disease states, activated T cells produce RANK-L and pro-inflammatory cytokines such as TNFα, IL-1, or IL-11, all of which can induce RANK-L expression in osteoblasts and bone marrow stromal cells (97) . Thus, it appears that T cells promote bone resorption directly via RANK-L expression and indirectly via expression of pro-inflammatory cytokines that mediate RANK-L expression in non-T cells ( Figure 5 ). These results are in line with the findings that T cells and non-T cell populations express RANK-L in arthritic joints. Inhibition of RANK-L has no effect on inflammation but completely prevents bone loss and protects cartilage (17) . Bone resorption induced by local injection of IL-1β or TNFα over the calvaria of mice can be blocked by concurrent systemic injection of OPG, which indicates that RANK-L is the mediator of the bone-damaging effects of TNFα and IL1-β in vivo (98) . Although inhibition of TNFα and IL-1 using soluble receptor antagonists to some extent prevents inflammation and bone loss in arthritis (7, 99, 100) , inhibition of RANK-L function via OPG might therefore prevent bone destruction and cartilage damage in arthritis irrespective of the initial trigger.
Reduced bone mineral densities can also be seen in many human diseases such as adult and childhood leukemia (101) , chronic infections such as hepatitis C or HIV (102) , autoimmune disorders such as diabetes mellitus (103) and lupus erythematosus (104) , allergic diseases such as asthma (105), lytic bone metastases in multiple cancers such as breast cancer (106), and of course arthritis (89) . These osteopenic disorders can cause irreversible crippling, thereby severely disrupting the lives of significant numbers of patients. For example, many patients with lupus require hip replacement surgery, and essentially all children that survive leukemia experience severe bone loss and growth retardation. In North America and Europe, 1 in 100 people develop RA and 1 in 10 people develop osteoarthritis. In addition, T cell-derived RANK-L contributes to alveolar bone resorption and tooth loss in an animal model that mimics human periodontal disease. The alveolar bone resorption around the teeth can be inhibited with OPG (107) . Moreover, it should be noted that OPG can prevent cancer cell-induced bone destruction (108) (109) (110) , cancer metastases-associated bone pain, and painrelated neurochemical reorganization of the spinal chord (111) . In most of these osteopenic disorders, disease pathogenesis correlates with the activation of T cells ( Figure 5) .
However, short-term activation of T cells does not result in any detectable bone loss, not even in some chronic T cell and TNFα-mediated diseases such as ankylosis spondylitis (112) . Moreover, T cells are working constantly to fight off the universe of foreign particles in which we live, so, at any point in time, some T cells are activated (113) . What is it that prevents these T cells from causing extensive bone loss every time we have an infection? A crucial counter-regulatory mechanism, by which activated T cells can inhibit the RANK-L-induced maturation and activation of osteoclasts has been recently discovered (Figure 3) (114) . It turns out that interferon-γ blocks RANK-L-induced osteoclast differentiation in vitro. Moreover, interferon-γ receptor knockout mice develop more bone destruction in inflammatory arthritis than do normal mice. Mechanistically, interferon-γ can activate the ubiquitin-proteasome pathway within the osteoclasts, resulting in the degradation of TRAF6. Thus, it appears that interferon-γ can prevent uncontrolled bone loss during inflammatory T cell responses. Moreover, T cell-derived IL-12 alone, and IL-12 in synergy with IL-18, inhibits osteoclast formation in vitro (115) , and IL-4 can abrogate osteoclastogenesis through STAT6-dependent inhibition of NF-κB signaling (116, 117) . Thus, multiple T cell-derived cytokines might be able to interfere with RANK signaling and therefore with osteoclastogenesis and osteoclast functions. In the future it will be interesting to determine the mechanisms that control the balance between T cell-mediated bone loss and inhibition of osteoclastogenesis. Nonetheless it has become clear now that inhibition of RANK-L-mediated activation of RANK via OPG or a related molecule ameliorates many osteopenic conditions. RANK-L inhibition appears to be the most rational and advisable strategy to prevent bone destruction in multiple diseases, to possibly eradicate major human diseases such as osteoporosis, to curtail crippling, and to limit tooth loss, diseases that affect millions of people.
Bone Loss, Mammary Gland Formation, and Mammalian Evolution
The expression of RANK-L and OPG is regulated by multiple hormones and cytokines shown to affect the development and activation of osteoclasts, including 25-dihydroxyvitamin D3, IL-1, IL-11, PGE 2 , calcitonin, and TNFα (11) . Intriguingly, expression of RANK-L and OPG is also strongly influenced by the female sex hormones progesterone and estrogen, and by hormones involved in reproduction and lactation such as prolactin and parathyroid hormone-related peptide (PTHrP) (118) . Reduction of ovarian function following menopause in women, and ovariectomy in animal models, result in osteoporosis and fractures, conditions that can be completely reversed at least in animals by treatment with OPG (38) . However, the evolutionary and functional rationale for RANK-L/OPG regulation by reproductive hormones and the prevalence of hormonally regulated and gender-biased osteoporosis in older females were not known.
In mammals, sex and pregnancy hormones control mammary gland morphogenesis and formation of a lactating mammary gland. Mammary gland morphogenesis proceeds in distinct steps, beginning with a fetal mammary anlage that undergoes ductal elongation and branching (119) . During pregnancy, increased ductal side branching and development of lobulo-alveolar structures result from the expansion and proliferation of ductal and alveolar epithelium (120) . Formation of a lactating mammary gland provides essential nourishment to mammalian newborns in the form of milk. Calcium is an important component of milk, and the main source of calcium for a newborn mammal is its mother's breast milk (121) . Calcium transport from mothers to the fetus and neonates is a vital process to preserve species. Deficits in maternal calcium transfer or calcium handling in the offspring have severe consequences for newborns, ranging from rickets to heart and brain defects (122) . Mothers meet the increased requirements for calcium during pregnancy and lactation by doubling their intestinal calcium absorption and demineralizing their skeletons via activation of bone-resorbing osteoclasts (123) .
Surprisingly, mice lacking RANK-L or its receptor RANK fail to form lobuloalveolar mammary gland structures during pregnancy and show a complete block in the formation of a lactating mammary gland, leading to the death of newborn pups. RANK-L expression in mammary epithelial cells is induced by pregnancy hormones, whereas the RANK is constitutively expressed on these cells. Transplantation and local RANK-L-rescue experiments in rankl −/− and rank −/− pregnant females showed that RANK-L acts directly on RANK-expressing mammary epithelial cells. The effects of RANK-L are autonomous to epithelial cells. The mammary gland defect in female rankl −/− mice is characterized by enhanced apoptosis and by failures in proliferation and Akt/PKB activation in lobulo-alveolar buds that can be reversed by recombinant RANK-L treatment. Thus, RANK-L and RANK, the master regulators of skeletal calcium release, are essential for the formation of the lactating mammary gland, the organ required for transmission of maternal calcium to neonates in mammalian species. Importantly, these data provided a novel function for TNF and TNFR family proteins and a new paradigm in the formation of a lactating mammary gland.
In phylogenetic evolution, the formation of lactating mammary glands is a relatively recent event, occurring when the first mammals appeared about 200 million years ago. Thus, mammals took a gene product that is the master regulator of bone metabolism and calcium turnover in the whole organism and subverted it to stimulation of mammary gland development during pregnancy. The balance between RANK-L, RANK, and the decoy receptor OPG is critical for the regulation of bone loss in osteoporosis, arthritis, and lytic bone metastases (118) . Osteoporosis affects hundreds of millions of people, particularly postmenopausal women. Intriguingly, genetic and functional models have shown that osteoclast-regulated bone remodeling is under the control of powerful sex and pregnancy hormones (11) . When estrogen production falls, such as occurs in ovariectomy models in animals or in postmenopausal women, induction of OPG is decreased, allowing uncontrolled demineralization of bone by RANK-L-stimulated osteoclasts (38) . Osteoporosis is strongly associated with increased morbidity and premature death in older women. The evolutionary question then arises, why has the RANK-L/RANK/OPG system, a key regulator of a structural organ such as the skeleton, come under the regulatory umbrella of reproductive hormones? Our results provided an unexpected molecular and evolutionary explanation for gender bias and the high incidence of osteoporosis in females. The strong bias toward bone loss in postmenopausal women may be due to the fact that the RANK-L/RANK/OPG system is essential for reproduction and the survival of mammalian offspring.
The transcription of the decoy receptor OPG is also regulated by pregnancy hormones, particularly estrogen (54). Thus, local or systemic OPG may contribute to mammary gland formation during pregnancy. However, opg −/− females (40) and females from three different OPG-overexpressing transgenic lines (38) showed normal breeding and mammary gland formation (our own unpublished data). Moreover, implantation of soluble OPG pellets into wild-type pregnant females at day 13.5 of pregnancy did not affect any aspect of mammary gland development (J. Tata, Y. Y. Kong, J. M. Penninger, unpublished). Thus, high systemic or local levels of OPG apparently cannot inhibit RANK-L and RANK interaction, implying that RANK-L acts locally on the same or neighboring epithelial cells. The action of OPG and the connection of RANK-L/RANK with pregnancy hormones also provide further insights into the regulation of bone loss during pregnancy. The binding of RANK-L to RANK on mature osteoclasts triggers their activation that then leads to release of calcium from the skeleton. OPG competes with RANK-L for binding to RANK and thus is a potent inhibitor of osteoclast differentiation and activity. Since estrogen enhances OPG expression on osteoblasts, we suggest that increased estrogen levels may protect the maternal skeleton via OPG during pregnancy. After giving birth, maternal estrogen levels rapidly decline, leading to decreased OPG and permitting the mobilization of calcium from the bones for lactation. Although this hypothesis explains clinical and experimental observations in animal models and humans, e.g., calcium-release from the bone due to osteoclasts activation is predominant in the third trimester of gestation and during lactating (121, 123) , it awaits proper testing.
During osteoclast development, CSF-1 and RANK-L cooperate to stimulate the differentiation of hematopoietic progenitors into mature multinucleated osteoclasts (13) . CSF-1 provides the survival signal, whereas RANK-L is the critical factor for osteoclast lineage determination. In contrast to the synergy between CSF-1 and RANK-L in osteoclastogenesis, CSF-1 appears to act independently of RANK-L/ RANK during mammary gland formation. Unlike rankl −/− and rank −/− mice, csf-1 −/− mice show increased lobulo-alveolar development of mammary epithelium during pregnancy and ovarian defects (124) . Thus, it appears that RANK-L/ RANK has a specific and unique role in mammary gland development that is regulated by pregnancy hormones. Mice deficient for the stat5a, cyclin D1, or prolactin receptor genes have defects in mammary gland development similar to those observed in rankl −/− and rank −/− females (119, 125, 126) , which suggests that RANK-L/RANK, Cyclin D1, Stat5a and/or prolactin might cooperate to stimulate lobulo-alveolar development. The exact functional and genetic relationships between RANK-L/RANK and pregnancy hormones, signaling molecules, and cell cycle regulatory molecules await elucidation.
These data have another intriguing implication. Both RANK-L and RANK are required for lymph node organogenesis, and RANK-L expressed on T cells provides activation and survival signals to dendritic cells. DCs, which express OPG, are specialized antigen-presenting cells that initiate and integrate immune responses. Like calcium uptake, immune responses must be modified during pregnancy so that a mother does not reject her allogeneic fetus, although the same mother can still reject an allogeneic skin transplant. Other examples of immune system alterations include the observed amelioration of clinical symptoms of multiple sclerosis during pregnancy, and the onset of severe T cell-regulated food allergies in some pregnant women (127, 128) . Thus, pregnancy is associated with alterations to the immune system that do not impair the general response to infections but lead to selective immunological adjustments (127) . Moreover, like osteoporosis, the development of autoimmunity shows a gender bias, and various sex/pregnancy hormones such as estrogen and prolactin influence the function and development of various lymphocyte populations (129, 130) . Since RANK-L, RANK, and OPG provide a genetic interface between the immune system, bone remodeling, and formation of a lactating mammary gland, this system is an intriguing starting point to address these questions at the genetic level.
CONCLUSIONS
RANK-L, its receptor RANK, and the decoy receptor OPG are the key regulators for osteoclast development and the activation of mature osteoclasts ( Figure 5) . Surprisingly, the same molecules that regulate osteoclastogenesis were identified as a key factor in early differentiation of thymocytes and B cell precursors and the development of lymph nodes and Peyer's patches. In the immune system, RANK-L is produced by activated T cells and acts as a potent survival factor of DCs. The understanding and manipulation of DC fate by RANK-L/RANK provides a new avenue for anti-tumor vaccination and the treatment of autoimmune diseases. RANK-L produced by activated T cells can directly induce osteoclastogenesis. Systemic or local activation of T cells triggers bone loss via expression of RANK-L. These findings provide the molecular explanation for bone loss associated with diseases having immune system involvement, such as adult and childhood leukemias, autoimmunity, and various viral infections. Inhibition of RANK-L function via OPG or a related molecule might therefore ameliorate many osteopenic conditions and prevent bone destruction and cartilage damage that ultimately cause crippling in arthritis. Moreover, RANK-L and RANK, the master regulators of skeletal calcium release, are essential for the morphogenesis of a lactating mammary gland, and they provide an evolutionary rationale for hormonal regulation of osteoporosis. 
Figure 2
Regulation of osteoclast formation in bone tissues. Calciotropic factors such as vitamin-D3, prostaglandin E2, IL-1, IL-11, TNFα and glucocorticoid induce RANKL expression on osteoblasts. RANKL binding to the RANK expressed on haematopoietic progenitors activates a signal transduction cascade that leads to osteoclast differentiation in the presence of the survival factor CSF-1. Moreover, RANKL stimulates bone resorbing activity in mature osteoclasts via RANK. OPG produced by osteoblasts acts as a decoy receptor for RANKL and inhibits osteoclastogenesis and osteoclast activation by binding to RANKL. TGFβ released from bone during active bone resorption has been suggested as a feedback mechanism by upregulating OPG level. Estrogen can enhance OPG production on osteoblasts which is a possible explanation of postmenopausal osteoporosis following estrogen withdrawal. The balance between RANKL and TRAIL levels at late stages of immune responses might determine the fate of DCs. Manipulation of DC fate via TRAIL, CD40L, RANKL, and OPG, could be used to optimize DC-based anti-tumor vaccination protocols and to treat autoimmune diseases. It should be noted that DC development and in vitro functions for T-cell activation appear normal in rankl and rank mutant mice. The functional capacity and longevity of rankl and rank mutant DCs in vivo needs to be addressed.
Figure 5
Activated T cells affect bone physiology. Activated T cells produce cytokines such as TNFα, IL-1, IL-11, and IL-17 that lead to RANKL expression on osteoblasts. Moreover, activated T cells directly express and produce RANKL that induces osteoclast formation and activation. The soluble decoy receptor for RANKL, OPG, blocks both pathways. Inhibition of RANKL via OPG might be useful to treat osteoporosis, crippling in arthritis, osteopenic disorders such as Paget's disease, and bone loss and pain associated with bone metastases.
